I mean they might post $2.50-$3.00 for 2021, but stock already at 25+ PE going forward. The one thing that could propel it further would be to find out that a large % of non active thryroid disease patients(5 times the size of the active group) would largely take Tepezza as well as the active(near 100% expected to take Tepezza). Right now at $72, $1B from Tepezza is already being priced in IMO, which is not far from what was expected from the entire active thyroid group. Therefore I'd be a seller here at $72 today.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.